More News

Oculus Plans to Debut Pentacam AXL Wave at ESCRS Congress in Paris

Oculus announced Aug. 13 that it plans to introduce its next-generation Pentacam anterior eye scanner—the Pentacam AXL Wave—at the 2019 ESCRS Congress in Paris in September. The German company said...

Aerie Initiates First Human Trial of AR-13503 Sustained-Release Implant for Wet AMD and DME

Aerie Pharmaceuticals, of Durham, North Carolina, announced Aug. 20 that it had begun patient dosing in a first-in-human clinical trial of AR-13503 sustained-release implant in patients with wet ag...

AcuFocus Completes Enrollment for US IDE Clinical Trial of IC-8 Lens

AcuFocus announced Aug. 14 that it had completed enrollment in its pivotal US study of the company’s IC-8 small aperture IOL. Al Waterhouse, AcuFocus president and CEO, said the study was on track ...

Alcon Reports Q2-2019 Revenue of $1.9 Billion, Up 2 Percent Year Over Year

Alcon reported Aug. 20 that its worldwide revenue in Q2-2019 reached $1.9 billion, an increase of 2 percent compared with Q2-2018, or 5 percent on a constant currency basis. The company, whose US h...

Graybug Vision Secures $80 Million in Series C Funding to Advance Retina, Glaucoma Programs

Graybug Vision, of Redwood City, California, announced Aug. 20 that it had secured $80 million in a Series C financing. Graybug is developing long-acting therapies for ocular diseases, including we...

ZipLine Medical Achieves Superior Results in Two New Studies

ZipLine Medical announced Aug. 13 that two peer-reviewed studies of its Zip Surgical Skin Closure were published, indicating that it is superior to metal staples. The first study, conducted by Rodn...

American Academy of Stem Cell Physicians Offers Board Certification

The American Academy of Stem Cell Physicians (AASCP) proctored a three-hour written certification exam at its scientific congress Aug. 2-4. This is the first certification program available for ste...

NuVasive Announces 10 Thousand Implants of Its Precice System

NuVasive posted Aug. 14 that its Precice System for limb lengthening has been implanted in 10 thousand patients. The system can lengthen a femur, tibia, or humerus by up to 80 millimeters via an Ex...

MIGS Devices Continue to Expand Use of Glaucoma Surgery

Voluntary recall of the Alcon CyPass in 2018 slowed the adoption rate of these stents and opened the door for alternatives. Minimally invasive glaucoma surgery (MIGS) stents account for nearly half...

Harrow Health Reports 46 Percent Increase in Ophthalmic Revenue in Q2-2019

Harrow Health reported Aug. 14 that its ImprimisRx ophthalmology unit had Q2-2019 revenue of $12.1 million, a 46 percent increase over Q2-2018. Harrow, now located in Nashville, Tennessee, also ann...

Carl Zeiss Meditec Continues Strong Growth Trend After Nine Months of FY2018-2019

Carl Zeiss Meditec reported Aug. 9 that revenue for its Ophthalmic Devices strategic business unit in nine months of fiscal year 2018-2019 totaled $852 million (€762.7 million), an increase of 12 p...

Peer-Reviewed Study Shows EyeArt AI Screening System for DR is Accurate, Consistent, and Fast

The peer-reviewed journal Diabetes Technology and Therapeutics, in a study of more than 100 thousand consecutive diabetic patient visits analyzed using the EyeArt AI eye screening system from Eyenu...

Lineage Cell Therapeutics Gets NIH Grant for Program to Generate 3-D Retinal Tissue

Lineage Cell Therapeutics, of Carlsbad, California—formerly BioTime—announced Aug. 13 that it had been awarded a new $670,621 Small Business Innovation Research grant to advance its Vision Restorat...

Regeneron Ebola Treatment Shows Promise; Study Is Stopped Early

Two experimental Ebola drugs—one developed by Regeneron, maker of Eylea—showed survival rates of as much as 90 percent in a clinical trial in Congo. The trial of four treatments was halted, and now...

ProQR Gets IND, Will Start Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

ProQR Therapeutics announced Aug. 12 that the US FDA had cleared its investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a Phase I/II trial this year....

MeiraGTx Hopes to Raise $75.2 Million with Sale of Ordinary Shares

Gene therapy company MeiraGTx Holdings, of New York, announced Aug. 8 an underwritten sale of 3.2 million of its ordinary shares at a public offering price of $23.50 per share. In addition, MeiraGT...

NovaBay Announces Pricing of Two Stock Offerings, Hopes to Raise $6.9 Million

NovaBay Pharmaceuticals, maker of the ophthalmic antimicrobial spray Avenova, announced Aug. 9 that it had made a deal with non-US institutional investors for the sale of preferred stock, automatic...

Ash Attia joins Bionic Vision Technologies as CEO

Australian company Bionic Vision Technologies announced July 22 that Ash Attia has joined the company as chief executive officer. Attia has over 30 years of senior executive management experience i...

Humana Sues Mallinckrodt over H.P. Athcar Gel, Taking Aim at ‘Ill-Gotten’ Gains

Health insurer Humana has filed a federal lawsuit in California, alleging that Mallinckrodt, maker of H.P. Acthar Gel, has profited from a widespread campaign to stifle competition and pay doctors ...

FDA Approves Prefilled Syringe for Eylea Injection

Regeneron, of Tarrytown, New York, announced Aug. 13 that the US FDA had approved its Eylea injection prefilled syringe. The company had filed a Chemistry, Manufacturing and Controls Prior-Approval...

Omeros’ Revenue Reaches a Record $26.8 Million for Q2-2019

Omeros’ revenue for Q2-2019 totaled $26.8 million—all relating to sales of Omidria—up 23 percent over Q1-2019, the Seattle firm reported Aug. 8. It was the company’s highest-revenue quarter to date...

TearLab Reports Q2-2019 Revenue of $5.9 Million, a Drop of 8.8 Percent

TearLab’s net revenue for Q2-2019 was $5.9 million, an 8.8 percent drop from $6.4 million in Q2-2018, the San Diego company announced Aug. 8. The company’s reported net loss for the 2019 second qua...

Penn Researchers Create Eye-on-a-Chip Device to Test Dry Eye Candidate

Researchers at the University of Pennsylvania have created an eye-on-a-chip device, complete with a blinking eyelid, to improve their understanding of dry eye disease. They studied the device as a ...

UPMC Launches Center of Excellence Program for Hip and Knee Replacements

UPMC Health Plan said Aug. 7 it has designated nine providers thus far for its new Center of Excellence program. This program provides credentials to approved orthopedic surgeons and hospitals who ...

Serbousek Will Succeed Mason as Orthofix CEO

Orthofix announced Aug. 5 that Jon Serbousek will become president and CEO after Brad Mason retires on Oct. 31. Serbousek has over 30 years of experience in the medical device industry, including w...

Life Spine Faces Civil Health Care Fraud Lawsuit

The US Department of Justice (DOJ) filed a civil health care fraud suit against Life Spine and specific executives within the organization, the DOJ reported July 25. Life Spine is accused of paying...

Roche, Novartis End Collaboration on Port Delivery System with Lucentis

Roche told analysts July 25 that it would continue to develop its Port Delivery System with Lucentis alone, because co-developer Novartis “decided to go a different path.” Switzerland-based Roche s...

LENSAR’s Laser Revenue Increases 26 Percent in Q2-2019, PDL Reports

LENSAR recorded Q2-2019 revenue of $7.4 million from its LENSAR Laser System, representing a 26 percent increase over Q2-2018 and a 10 percent increase over Q1-2019, parent PDL BioPharma reported A...

US FDA Asks Kala for More Clinical Trial Data on Dry Eye Candidate

Kala Pharmaceuticals announced Aug. 8 that it had received a complete response letter from the US FDA regarding the company’s new drug application (NDA) for KPI-121 0.25% for the temporary relief o...

Eyewear Titan EssilorLuxottica Agrees to Buy GrandVision in $8 Billion Deal

EssilorLuxottica, the maker of Ray-Ban sunglasses, agreed July 31 to buy Dutch retailer GrandVision NV in a multibillion-dollar deal. Paris-based EssilorLuxottica agreed to buy control (77 percent ...

Harrow Health Forms Subsidiary to Develop Broad Spectrum Antimicrobial Molecule for Eye, Ear

Harrow Health, of Nashville, Tennessee, announced Aug. 2 that its newly formed subsidiary, Stowe Pharmaceuticals, had entered into an agreement with TGV Health to acquire worldwide rights to the Zi...

Australian Regulatory Agency Approves Iluvien Implant for DME

Australia’s Therapeutic Goods Administration has approved the Iluvien fluocinolone acetonide intravitreal implant for those who have vision impairment associated with chronic diabetic macular edema...

NuSight Medical Sells 5 Thousand NuLids Systems

NuSight Medical, of Rancho Santa Fe, California, announced Aug. 7 that the company had sold its 5 thousandth NuLids System. NuLids, launched in June 2018, is a doctor-prescribed, handheld medical d...

Opthea Meets Primary Endpoint in Phase IIb Study of OPT-302 in Wet AMD

Opthea, of Melbourne, Australia, announced Aug. 6 that its Phase IIb study of OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks, compared wi...

Aerie Reports $15.8 Million in Revenue for Q2-2019, Lowers Full-Year Guidance

Aerie Pharmaceuticals’ net product revenue rose to $15.8 million in Q2-2019, a 46 percent increase over Q1-2019, the Durham, North Carolina, company announced Aug. 7. The company said the long-term...

Avedro Reports Net Sales Up 63 Percent in Q2-2019

Avedro’s net sales grew to $10.3 million in Q2-2019, a 63 percent increase over Q2-2018 net sales of $6.3 million, the Waltham, Massachusetts, company announced Aug. 7. Avedro, developer of corneal...

Glaukos’ Net Sales Grow 36 Percent in Q2-2019

Glaukos’ net sales grew to $58.6 million in Q2-2019, a 36 percent increase over Q2-2018 net sales of $43.2 million, the San Clemente, California, company announced Aug. 7. Glaukos, maker of the iSt...

Glaukos to Acquire Avedro in All-Stock Transaction

Glaukos, maker of the iStent inject, and Avedro, developer of corneal cross-linking, announced Aug. 7 that the companies have entered into a definitive merger agreement under which Glaukos will acq...

Second Sight Reports 10 Argus II Implantations, $1.3 Million in Revenue in Q2-2019

Second Sight announced Aug. 7 that surgeons implanted 11 Argus II retinal prostheses worldwide in Q2-2019, resulting in revenue of $1.3 million, compared with 17 implantations and $1.9 million in Q...

EyePoint Reports Q2-2019 Net Revenue of $7.2 Million

EyePoint Pharmaceuticals reported Aug. 7 that its Q2-2019 net revenue totaled $7.2 million, compared with $715 thousand in Q2-2018. Net product revenue was $6.7 million, generated from sales of Yut...

Iridex Revenue Grows 1.2 Percent in Q2-2018

Iridex’ revenue for Q2-2019 was $10.4 million, a 1.2 percent increase over $10.3 million in Q2-2018, the company reported Aug. 6. The Mountain View, California, company said it shipped 85 Cyclo G6 ...

Allergan Reports Q2-2019 Total Revenue of $4.09 Billion

Allergan reported Aug. 6 that its Q2-2019 net revenue totaled $4.09 billion, a 0.8 percent decrease from $4.12 billion in Q2-2018. Dry eye drug Restasis’ net revenue in the US was $310.9 million, a...

Bausch + Lomb Reports Revenue Edging Down in Q2-2019 to $1.208 Billion

Bausch + Lomb posted revenue of $1.208 billion in Q2-2019, a slight decrease (+3 percent on a constant currency basis) from Q2-2018 revenue of $1.209 billion. The New Jersey-based eye care segment ...

Regeneron’s Net Sales of Eylea in the US Increase 17 Percent in Q2-2019

Regeneron’s US net sales of Eylea in Q2-2019 totaled $1.16 billion, a 17 percent increase over Q2-2018, the Tarrytown, New York, company announced Aug. 6. Bayer, which licenses Eylea outside the US...

Kala Reports Q2-2019 Revenue of $2.1 Million for Inveltys

Kala Pharmaceuticals reported Aug. 6 that its Q2-2019 revenue for Inveltys totaled $2.1 million, compared with $1.4 million for the first quarter of 2019, representing quarter-over-quarter growth o...

Orthopedic US FDA 510(k) Clearances

During the past month, 45 orthopedic devices received FDA clearance. A third of the devices (15) were spine implants. Six of the spine devices were for fixation: one laminectomy plate from NuVasive...

EU MDR Updates May Change Global Product Approval and Distribution Patterns

Since 1992, medical devices have gained access to the European market by CE marking under regulations set forth in the Medical Device Directive (MDD). In May 2020, the Medical Device Regulation (MD...

Conformis and Regent Surgical Health Partner to Improve Outpatient Joint Replacement

Medical-technology company Conformis announced July 15 that is has a new partnership with Regent Surgical Health, a privately owned ASC development and management center. The goal of the partnershi...

Monthly Orthopedic Deals

From mid-June to mid-July, nine significant orthopedic deals took place: three venture capital transactions, three stock offerings, and three acquisitions. The largest disclosed sum—$12 million—was...

UKA Popularity May Be Aided by Surgical Robots

Unicompartmental knee arthroplasty (UKA) is once again on the agenda at professional meetings and is increasingly mentioned by implant manufacturers when discussing product pipelines. UKA promises ...

Robots Are Disrupting the Orthopedic Surgery Market

Orthopedic robots offer an unprecedented opportunity to reduce surgical complications and operating time, improve results, and extend the life of implants. These benefits stem from increased precis...

FDA Approves Trial of Stem Cells for OA

Personalized Stem Cells announced July 24 that the US FDA approved its Investigational New Drug (IND) application for use of adipose-derived stem cells to treat osteoarthritis (OA). The first study...

U.S. News & World Report Ranks HSS First in Orthopedics for Tenth Year

For the past 10 years, Hospital for Special Surgery (HSS) in New York has been named first in orthopedics by U.S. News & World Report. The 2019-2020 rankings compared over 4,500 medical centers in ...

Konica Minolta’s DDR Wins AHRA Innovation Award

Konica Minolta Healthcare Americas reported July 31 that its Dynamic Digital Radiography (DDR) technology won the 2019 Innovation Award at the annual meeting of the AHRA: Association for Medical Im...

CVS Tests Knee Replacement Strategy With Aetna

CVS Health announced July 23 that it will be conducting a pilot program for knee replacements for those insured by Aetna’s Medicare Advantage and commercial policies. This latest initiative to prov...

Mylan and Upjohn, a Division of Pfizer, to Combine in All-Stock Deal

Mylan and Pfizer announced July 29 a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic drugs business, creating a new global pharmaceutical company. The Upj...

Monovision Can Dramatically Alter Depth Perception, Researchers Find

A team from the University of Pennsylvania and the Institute of Optics in Madrid recently discovered that monovision can cause dramatic misperceptions of the distance and 3-D direction of moving ob...

J&J Vision Launches New Surgical Vision Experience Center in Jacksonville, Florida

Johnson & Johnson Vision announced on July 31 the launch of its Surgical Vision Experience Center at the Johnson & Johnson Institute in Jacksonville, Florida. The center will serve as J&J Vision’s ...

MicroSurgical Technology Releases Cutter for Trimming MIGS Implants

MicroSurgical Technology, of Redmond, Washington, announced July 25 that it has developed the MST 19-gauge Ahmed Micro Stent Cutter. The company said it was addressing the challenge of microstent r...

BioTime Changing its Name to Lineage Cell Therapeutics

BioTime, of Alameda, California, announced July 31 that it is launching a new corporate brand, including a change of its name to Lineage Cell Therapeutics, effective Aug. 12. In connection with the...

Aequus Signs Deal with Medicom for Canadian Distribution Rights of Ophthalmic Products

Aequus Pharmaceuticals, of Canada, announced July 29 that it had signed an exclusive distribution agreement with Medicom Healthcare, a UK-based pharmaceutical company with a focus on preservative-f...

Alkahest Phase IIa Study of Oral Wet AMD Candidate Meets Primary and Secondary Endpoints

Alkahest, of San Carlos, California, announced July 29 that its Phase IIa trial of AKST4290, an orally administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase ...

Altris AI Algorithm for Detecting Retinal Conditions on OCT Scans Gets CE Marking

Altris, an artificial intelligence (AI) health care company based in Chicago, announced July 31 that it had received CE marking for its Standard Functionality software for detection of retinal cond...

Philanthropist Pledges $2 Million for Biotech Solutions to Corneal Blindness

Tej Kohli, a London-based billionaire in the tech industry, has pledged $2 million to Massachusetts Eye and Ear in Boston to fund innovation in research to cure corneal blindness. Kohli says in his...

Bausch + Lomb Initiates First Clinical Trial for Technolas Teneo Excimer Laser in US

Bausch + Lomb announced July 31 that it had initiated the first in a series of US clinical trials to evaluate the safety and efficacy of the Technolas Teneo excimer laser for vision correction surg...

EMA Grants PRIME Access to ProQR’s Sepofarsen for LCA10

Netherlands-based ProQR Therapeutics announced July 29 that its sepofarsen (QR-110) drug candidate, being developed for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access ...

EU Panel Recommends Lucentis for Approval to Treat Retinopathy in Premature Infants

The Swiss company Novartis announced July 26 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Lucentis for the treat...

Novartis, Mundipharma Ink Partnership for Better Eye Drug Access in 3 Asian Countries

Novartis, of Switzerland, and UK-based Mundipharma announced July 26 that they had signed an agreement for the marketing, sales, and distribution rights of Novartis ophthalmic medicines in Taiwan, ...

Ocular Therapeutix Announces Early Assignment of Permanent J-Code for Dextenza

Ocular Therapeutix, of Bedford, Massachusetts, announced July 26 that the Centers for Medicare and Medicaid Services (CMS) had assigned a specific and permanent reimbursement J-code for Dextenza, i...

Opthea’s Patent Application for OPT-302 to be Granted by European Patent Office

Opthea, of Melbourne, Australia, announced July 30 that the European Patent Office had signaled that it intended to grant Opthea’s European patent application covering OPT-302, a soluble form of va...

STAAR Surgical Reports Record Second Quarter Results for Total Revenue, ICL Sales, and ICL Units

STAAR Surgical reported July 31 that its net sales for Q2-2019 were $39.7 million, up 17 percent (19 percent on a constant currency basis) from the same quarter a year ago. It also reported record ...

Alimera Highlights Strong International Growth in Announcing Q2-2019 Results

Alimera Sciences, of Atlanta, saw its consolidated net revenue grow 2 percent in the second quarter of 2019 to $10.9 million, compared to $10.7 million during the second quarter of 2018. US net rev...

Biophytis Withdraws SEC Paperwork for Planned IPO, Says Market Isn’t Favorable

Biophytis, of Paris, has withdrawn its SEC paperwork for an initial public offering of shares under the symbols BPTS on the Nasdaq and ALBPS on Euronext Growth Paris. The company cited “unfavorable...

Laser Maker Lumibird Reports Medical Division Revenue Up 12.2 Percent in Q2-2019

Lumibird reported July 29 that total company revenue hit €51.3 million ($57.2 million US) for the first half of 2019, up 21.2 percent (20.3 percent on a constant currency basis) over the same perio...

MedShape’s DynaNail Fusion System Achieves Positive Clinical Results

MedShape announced July 23 that two clinical studies concluded that the DynaNail Tibiotalocalcaneal (TTC) Fusion System effectively addresses high-risk patients with challenging clinical presentati...

Miach BEAR Restores Torn ACLs to the Quality and Size of a Natural ACL

On July 23, Miach Orthopedics disclosed results of a new study comparing ACLs repaired with the company’s Bridge-Enhanced ACL Repair (BEAR) implant and ACLs repaired with hamstring autograft. MRI i...

Eight New Studies Support the Benefits of ExactechGPS for Knee and Shoulder Replacements

Exactech announced June 18 that eight new studies demonstrate the advantages of its ExactechGPS computer-assisted technology for knee and shoulder replacement surgeries. Evaluations of the TKA Plus...

Humana Expands Reach of Bundled Payment Models

Humana announced July 17 that new providers have joined its spinal fusion surgery and hip or knee replacement bundled payment models. This will extend Humana’s value-based care programs to more Med...

Zeiss’ New US Headquarters on Track for Completion in Q4-2020

Zeiss has completed the steel “topping out” phase of its new US headquarters for Zeiss medical technology, the German company announced July 15. The 208,650-square-foot facility is being constructe...

Microsoft Code Jumper Aims to Spark Computer Science Interest in Blind Children

Microsoft has announced plans to transfer the research and technology behind Code Jumper—a physical programming language that is designed to be inclusive of children with all ranges of vision—to th...

PolyActiva Completes Enrollment in Glaucoma Implant Safety Study, Raises $10 Million

PolyActiva announced July 23 that it had completed patient enrollment for its Phase I clinical trial of its biodegradable, slow-release ocular implant for the treatment of glaucoma. The Australian ...

Oyster Point Enrolls First Subject in Phase III Trial of Nasal Spray for Dry Eye

Oyster Point Pharma of Princeton, New Jersey, announced July 24 that it had enrolled the first subject in its Phase III trial of its OC-01 nasal spray for dry eye. The study, which aims to enroll 7...

Ellex Appoints Maieli as Interim CEO; Wallace Exits After Three Months

Ellex Medical Lasers announced July 19 that it had appointed of Maria Maieli as interim CEO. Ellex’s current CEO, Gerald Wallace, told the board that he intended to resign from the company. He was ...

Omeros’ Omidria Receives Product-Specific J-Code from CMS

Seattle-based Omeros announced July 24 that the Centers for Medicare and Medicaid Services (CMS) had confirmed its decision to assign a permanent, product-specific J-code for Omidria. Surgeons use ...

Amgen and Allergan’s Avastin Biosimilar Now Available in the US

Amgen and Allergan announced on July 18 that Mvasi, a biosimilar to Avastin (bevacizumab), is now available in the US. Mvasi, the first oncology therapeutic biosimilar approved by the US FDA, is ap...

IVERIC bio Advances LCA10 Minigene Program, Expands into USH2A-Related Inherited Retinal Diseases

IVERIC bio announced July 23 that it had entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize gene therapy ...

Allergan and Editas Medicine Initiate Phase I/II Trial of Gene Therapy for the Treatment of LCA10

Ireland-based Allergan and Editas Medicine, of Cambridge, Massachusetts, announced July 25 that their Phase I/II clinical trial of AGN-151587 (EDIT-101) is open for patient enrollment. AGN-151587 i...

Bausch + Lomb Introduces FreeFlow Infusion System, New 23-Gauge Bi-Blade Cutter

Bausch + Lomb says its new FreeFlow infusion system for retinal surgery allows for higher level of infusion flow compared with previous generation infusion lines—supporting the efficient vitreous r...

EyePoint Announces Early Assignment of CMS J-Code for its Yutiq Implant

EyePoint, of Watertown, Massachusetts, announced July 25 that the Centers for Medicare and Medicaid Services (CMS) had assigned a permanent reimbursement J-code for Yutiq, its implant for chronic n...

Glaukos Enters Licensing Deal with Intratus for Transdermal Drug Delivery Platform

Glaukos announced July 22 that it had entered into a licensing agreement with Intratus for its noninvasive drug delivery platform designed to treat dry eye disease, glaucoma, and other corneal diso...

Ocuphire Pharma Raises Over $5 Million to Complete Nyxol Phase II Trials

Ocuphire Pharma announced July 22 that it had closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol...

Roche Reports Strong Performance in First Half of 2019; Lucentis Sales up 10 Percent in US

Roche reported sales of 30.5 billion Swiss francs (US $30.94 billion) for the first half of the year, a 9 percent increase on a constant currency basis. The Swiss company said July 25 that sales of...

GenSight Ready to Explain Baffling Gene Therapy Results to Regulators

It’s a big summer for GenSight. The 7-year-old Paris-based gene delivery company has a pre-submission meeting with the European Medicines Agency this month. GenSight CEO Bernard Gilly said that wil...

Glaukos CEO Tells OCTANe Attendees About Firm’s Early Days

Thomas Burns, president and CEO of Glaukos, provided an inside look at the challenging early days of the device maker in an interview kicking off the 2019 OCTANe Ophthalmic Technology Summit. The m...

2019 AOA Meeting Looks at Intersection of Optometric, Ophthalmic Practices

Optometrists often work in remote locations, with ophthalmologists available only intermittently, and these primary care eye doctors must tackle a range of eye diseases and injuries with available ...

Premium Monofocal IOLs Offer Better Intermediate Vision, Raise Questions of Market Impact

Premium monofocal IOLs launched by several leading companies—including J&J Vision and Santen—are expected to offer cataract patients improved intermediate vision, and in doing so add a layer to the...

Ocumension Licenses Blepharitis Candidate from Nicox for up to $13.5M, Plus Royalties

Nicox and Ocumension Therapeutics announced July 2 that they had entered into an exclusive licensing agreement for the development and commercialization of Nicox’s blepharitis drug candidate NCX 42...

Carl Zeiss Meditec Invests in MicroOptx, an Early-Stage MIGS Device Maker

Carl Zeiss Meditec announced June 20 that it is now a shareholder of MicroOptx, a privately held company in Minneapolis focused on minimally invasive glaucoma surgery (MIGS) devices for surgical tr...

White House Pivots on Drug Price Strategy, Drops Proposed Rebate Ban

The Trump administration is now focused on lowering US drug prices by tying those prices to the lowest prices paid elsewhere, after scrapping plans to eliminate hidden rebates. Health Secretary Ale...

Alimera’s Iluvien Receives NICE Recommendation for Posterior Uveitis

Alimera Sciences announced June 20 that the UK’s National Institute for Health and Care Excellence (NICE) had recommended funding for Iluvien for noninfectious posterior uveitis. A NICE recommendat...

Want to Read Locked Articles?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 201 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2019 Market Scope, LLC. All Rights reserved.